Being a multitarget kinase inhibitor, sorafenib blocks tyrosine kinase signalling receptors (VEGFR, PDGFR, and RET) and inhibits downstream Raf serine/threonine kinase activity to prevent tumor growth by antiangiogenic, antiproliferative, or proapoptotic effects that promote tumor cell apoptosis [34]. Here, KDR is linked to neoplasm.